• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

β受体激动剂使用增加模式与致命或近乎致命哮喘的风险

Patterns of increasing beta-agonist use and the risk of fatal or near-fatal asthma.

作者信息

Suissa S, Blais L, Ernst P

机构信息

Dept of Epidemiology and Biostatistics, Montreal General Hospital, McGill University, Quebec, Canada.

出版信息

Eur Respir J. 1994 Sep;7(9):1602-9. doi: 10.1183/09031936.94.07091602.

DOI:10.1183/09031936.94.07091602
PMID:7995388
Abstract

The association between the use of inhaled beta-agonists by metered-dose inhaler and the risk of fatal or near-fatal asthma has been demonstrated. It shows that asthmatics who use one canister of beta-agonist per month more than the number used by other similar asthmatics have twice the risk of fatal or near-fatal asthma. The present investigation assesses the magnitude of this excess risk when an asthmatic increases his/her own monthly use of inhaled beta-agonists over time. From a previous nested case-control study of 129 deaths and near-deaths from asthma (cases) and 655 controls from a cohort of 12,301 asthmatics, the subset using at least 12 inhalers during the 12 month study period was identified (97 cases and 258 controls). A profile score, ranging 0-11, was formed to quantify the patterns of beta-agonist use over time for each subject, covering the entire spectrum extending from decreasing to increasing use. The relative risk was 15.2 (95% confidence interval (CI) 2.4-96.2) per unit increase of the profile score in subjects with a pattern of increasing beta-agonist use (profile score of 6.5 or more), but this relative risk was only 1.5 (95% CI 0.8-2.6) per unit when the profile score was less than 6.5 (non-increasing use). This relative risk was independent of the risk associated with the total quantity of beta-agonist use in the 12 month period, which remained around 1.6 (95% CI 1.3-2.0) per inhaler per month.(ABSTRACT TRUNCATED AT 250 WORDS)

摘要

定量吸入器使用吸入性β受体激动剂与致命性或接近致命性哮喘风险之间的关联已得到证实。结果显示,每月使用β受体激动剂吸入罐数量比其他类似哮喘患者多一罐的哮喘患者,发生致命性或接近致命性哮喘的风险要高出两倍。本研究评估了随着时间推移哮喘患者增加自身每月吸入性β受体激动剂使用量时,这种额外风险的程度。在之前一项针对12301名哮喘患者队列中的129例哮喘死亡和接近死亡病例(病例组)以及655名对照进行的巢式病例对照研究中,确定了在12个月研究期间使用至少12个吸入器的亚组(97例病例和258名对照)。为每个受试者形成了一个范围在0至11之间的概况评分,以量化β受体激动剂随时间的使用模式,涵盖从使用量减少到增加的整个范围。在β受体激动剂使用量呈增加模式(概况评分6.5或更高)的受试者中,概况评分每增加一个单位,相对风险为15.2(95%置信区间[CI] 2.4 - 96.2),但当概况评分小于6.5(非增加使用)时,每单位相对风险仅为1.5(95% CI 0.8 - 2.6)。这种相对风险与12个月期间β受体激动剂使用总量相关的风险无关,后者仍约为每月每个吸入器1.6(95% CI 1.3 - 2.0)。(摘要截断于250字)

相似文献

1
Patterns of increasing beta-agonist use and the risk of fatal or near-fatal asthma.β受体激动剂使用增加模式与致命或近乎致命哮喘的风险
Eur Respir J. 1994 Sep;7(9):1602-9. doi: 10.1183/09031936.94.07091602.
2
The use of beta-agonists and the risk of death and near death from asthma.β-激动剂的使用与哮喘导致的死亡及濒死风险
N Engl J Med. 1992 Feb 20;326(8):501-6. doi: 10.1056/NEJM199202203260801.
3
Is the association between inhaled beta-agonist use and life-threatening asthma because of confounding by severity?吸入性β-受体激动剂的使用与因严重程度混淆导致的危及生命的哮喘之间是否存在关联?
Am Rev Respir Dis. 1993 Jul;148(1):75-9. doi: 10.1164/ajrccm/148.1.75.
4
The case-time-control design.病例-时间-对照设计
Epidemiology. 1995 May;6(3):248-53. doi: 10.1097/00001648-199505000-00010.
5
A cohort analysis of excess mortality in asthma and the use of inhaled beta-agonists.哮喘患者超额死亡率及吸入性β受体激动剂使用情况的队列分析。
Am J Respir Crit Care Med. 1994 Mar;149(3 Pt 1):604-10. doi: 10.1164/ajrccm.149.3.8118625.
6
Case-control study of salmeterol and near-fatal attacks of asthma.沙美特罗与哮喘致死性发作的病例对照研究
Thorax. 1998 Jan;53(1):7-13. doi: 10.1136/thx.53.1.7.
7
Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use.与吸入性糖皮质激素使用相关的致命性和近乎致命性哮喘风险。
JAMA. 1992;268(24):3462-4.
8
Regular treatment with salmeterol and inhaled steroids for chronic asthma: serious adverse events.沙美特罗与吸入性糖皮质激素联合常规治疗慢性哮喘:严重不良事件
Cochrane Database Syst Rev. 2009 Jul 8(3):CD006922. doi: 10.1002/14651858.CD006922.pub2.
9
Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering beta (2 )agonists bronchodilators in asthma.压力定量吸入器与其他手持吸入装置在哮喘中递送β₂激动剂支气管扩张剂的临床有效性的系统评价
BMJ. 2001 Oct 20;323(7318):901-5. doi: 10.1136/bmj.323.7318.901.
10
Double trouble: impact of inappropriate use of asthma medication on the use of health care resources.双重麻烦:哮喘药物使用不当对医疗资源利用的影响
CMAJ. 2001 Mar 6;164(5):625-31.

引用本文的文献

1
Asthma: effect of excess short-acting β-agonist (SABA) inhaler prescriptions on healthcare resource utilisation.哮喘:短效β受体激动剂(SABA)吸入器处方过量对医疗资源利用的影响。
Br J Gen Pract. 2024 Jul 25;74(745):374-376. doi: 10.3399/bjgp24X739089. Print 2024 Aug.
2
The Acute Effects of the Use of Salbutamol and Ipratropium on the Heart Rates of Patients With Obstructive Airway Disease.沙丁胺醇与异丙托溴铵联用对阻塞性气道疾病患者心率的急性影响
Cureus. 2023 Oct 3;15(10):e46409. doi: 10.7759/cureus.46409. eCollection 2023 Oct.
3
Regular (up to 10 puffs 4-hourly) inhaled salbutamol should be prescribed at discharge after an asthma attack: myth or maxim?
哮喘发作后出院时应常规(每4小时最多10喷)开具吸入沙丁胺醇处方:误区还是准则?
Breathe (Sheff). 2023 Sep;19(3):230054. doi: 10.1183/20734735.0054-2023. Epub 2023 Oct 10.
4
Methods to assess COPD medications adherence in healthcare databases: a systematic review.评估医疗数据库中 COPD 药物依从性的方法:系统评价。
Eur Respir Rev. 2023 Sep 27;32(169). doi: 10.1183/16000617.0103-2023. Print 2023 Sep 30.
5
Open and Closed Triple Inhaler Therapy in Patients with Uncontrolled Asthma.开放三联和闭合三联吸入疗法治疗未控制哮喘患者的疗效比较。
Adv Respir Med. 2023 Jul 4;91(4):288-300. doi: 10.3390/arm91040023.
6
Gulf Asthma Diagnosis and Management in Adults: Expert Review and Recommendations.成人海湾地区哮喘的诊断与管理:专家综述与建议
Open Respir Med J. 2022 Jul 18;16:e187430642205230. doi: 10.2174/18743064-v16-e2205230. eCollection 2022.
7
Perceptions, attitudes, and behaviors of asthma patients towards the use of short-acting β2-agonists: A systematic review.哮喘患者对短效 β2-受体激动剂使用的认知、态度和行为:系统评价。
PLoS One. 2023 Apr 20;18(4):e0283876. doi: 10.1371/journal.pone.0283876. eCollection 2023.
8
Key recommendations for primary care from the 2022 Global Initiative for Asthma (GINA) update.2022 年全球哮喘倡议(GINA)更新:初级保健的主要建议。
NPJ Prim Care Respir Med. 2023 Feb 8;33(1):7. doi: 10.1038/s41533-023-00330-1.
9
A Call for the United States to Accelerate the Implementation of Reliever Combination Inhaled Corticosteroid-Formoterol Inhalers in Asthma.呼吁美国加快在哮喘治疗中使用缓解型吸入性糖皮质激素-福莫特罗联合吸入器的实施。
Am J Respir Crit Care Med. 2023 Feb 15;207(4):390-405. doi: 10.1164/rccm.202209-1729PP.
10
Salbutamol in the Management of Asthma: A Review.沙丁胺醇在哮喘管理中的应用:综述。
Int J Mol Sci. 2022 Nov 17;23(22):14207. doi: 10.3390/ijms232214207.